Raiffeisen Bank International AG Sells 5,777 Shares of IQVIA Holdings Inc. $IQV

Raiffeisen Bank International AG cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 47.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,500 shares of the medical research company’s stock after selling 5,777 shares during the period. Raiffeisen Bank International AG’s holdings in IQVIA were worth $1,256,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IQV. Financial Freedom LLC bought a new stake in IQVIA in the first quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in IQVIA in the first quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $27,000. Compass Financial Management LLC bought a new stake in IQVIA in the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in IQVIA during the 4th quarter valued at $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider W. Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 15,581 shares of company stock valued at $3,796,021 in the last quarter. 1.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. TD Cowen lifted their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. BMO Capital Markets upped their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Stock Down 1.6%

Shares of NYSE IQV opened at $267.34 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $44.00 billion, a PE ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18. The company’s fifty day simple moving average is $230.54 and its 200 day simple moving average is $192.66. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $271.80.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.